GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT00455923
- Locations
- 🇸🇪
GSK Investigational Site, Luleå, Sweden
No Resistance After Long Term Treatment SERETIDE
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00456313
- Locations
- 🇳🇱
GSK Investigational Site, Utrecht, Netherlands
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Biological: Immunotherapeutic GSK1572932ADrug: Cisplatin (CDDP)Drug: VinorelbineProcedure: Radiotherapy
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 71
- Registration Number
- NCT00455572
- Locations
- 🇬🇧
GSK Investigational Site, Southampton, United Kingdom
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
- Conditions
- Haemophilus Influenzae Type bNeisseria MeningitidisNeisseria Meningitidis-Haemophilus Influenzae Type b Vaccine
- Interventions
- Biological: MenitorixBiological: Infanrix IPV
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT00454987
- Locations
- 🇬🇧
GSK Investigational Site, Oxford, Oxfordshire, United Kingdom
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine 134612Biological: Menactra®
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 873
- Registration Number
- NCT00454909
- Locations
- 🇺🇸
GSK Investigational Site, Waipio, Hawaii, United States
A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients
- Conditions
- AsthmaMild Asthma
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00453778
Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612Biological: Mencevax™ACWYBiological: Fluarix™
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1352
- Registration Number
- NCT00453986
- Locations
- 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK233705
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00453687
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00453479
- Locations
- 🇳🇱
GSK Investigational Site, Zuidlaren, Netherlands
The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: GW805858
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT00453791
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom